The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinaemia.
Seven hyperprolactinaemic women were treated with the new, long-acting dopamine agonist pergolide mesylate. The treatment resulted in normalization of the prolactin secretion in four of the seven women and six of them experienced regular uterine bleedings. Four of the patients had previously discontinued bromocriptine because of adverse effects but had no problems to tolerate pergolide. One bromocriptine-resistant woman was unresponsive also to pergolide therapy. Reported side-effects in the seven women were mild and transient. Pergolide mesylate may be a valuable alternative to bromocriptine in the management of patients with hyperprolactinaemia.
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy* / Q000209:etiology; D001971:Bromocriptine / Q000627:therapeutic use; D003248:Constipation / Q000139:chemically induced; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use*; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D009325:Nausea / Q000139:chemically induced; D010479:Pergolide; D011388:Prolactin / Q000097:blood / Q000378:metabolism*; D013997:Time Factors
D004873:Ergolines; D010479:Pergolide; D001971:Bromocriptine; D011388:Prolactin